Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma

Table 2

Relationship between clinical pathologic characteristics and EGFR mutation.

Characteristic	Number of patients	EGFR mutation
		Positive	Negative
Age
>60	35	15	20	0.550
≦60	20	9	11
Sex
Male	25	7	18	0.031
Female	30	17	13
Smoking history
Current smoker	6	1	5	0.180
Ever smoker habit	17	6	11
Never	32	17	15
Stage
IIIa	2	1	1	0.760
IIIb	9	2	7
IV	44	21	23
Tumor Differentiation
Moderate	36	17	19	0.327
Poor	19	7	12
TTF1
Positive	45	20	25	0.542
Negative	10	4	6
ER- nucleus expression
Strong (≧6)	38	20	18	0.041
Weak	17	4	13
ER- cytosolic expression
Strong (≧6)	27	14	13	0.175
Weak	28	10	18
ER- nucleus expression
Strong (≧6)	39	17	22	0.611
Weak	16	7	9
ER- cytosolic expression
Strong (≧6)	21	11	10	0.227
Weak	34	13	21

EGFR mutation including exon 19 deletion and L858 point mutation in exon 21.